July 17th 2024
Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Enzalutamide Granted FDA Approval for Treatment of Patients With mCSPC
December 17th 2019Enzalutamide is now approved by the FDA for the treatment of metastatic castration-sensitive prostate cancer, making it the first oral agent to be approved for three different types of advanced prostate cancer, according to a press release from Pfizer.<br />
Read More
Olaparib Reported as the First Gene-Targeted Therapy to Benefit Patients With mCRPC
December 4th 2019A significant proportion of patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations responded well to treatment with olaparib in a phase II TOPARP-B trial, making olaparib the first targeted therapy to show benefit in this patient population, the Institute of Cancer Research reported in a press release.
Read More
MRTX849 Shows Safety, Tolerability in Treating KRAS G12C
November 29th 2019In patients whose solid<strong> </strong>tumors harbor a mutation in <em>KRAS </em>G12C, therapy with MRTX849 has produced promising responses and acceptable toxicity across 3 tumors types, according to data presented at the 2019 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics.
Read More
Onvansertib/Abiraterone Stabilizes PSA in 75 Percent of Patients With mCRPC
November 26th 2019The combination of onvansertib with abiraterone acetate decreased the prostate-specific antigen levels in most of the evaluable patients treated in a phase II study, which used the combination in adult patients with metastatic castration-resistance prostate cancer, according to a press release from onvansertib developer, Trovagene, Inc.
Read More
Very High Response Rate Seen in Phase III Advanced Prostate Cancer Study
November 19th 2019Male patients with advanced prostate cancer had a 97% response rate to relugolix, a gonadotropin-releasing hormone receptor antagonist, in the phase III HERO study, meeting the primary end point of the study. The trial also met all 6 of its key secondary end points, according to a press release from Myovant Sciences.
Read More
Examining the NCCN Recommendations for Genetic Testing in Prostate Cancer
November 12th 2019In an interview with Targeted Oncology during the 2019 Prostate Cancer Consensus Conference, James L. Mohler, MD, explained the reasons for changes to the NCCN guidelines on genetic testing and counseling in prostate cancer. He also discussed what needs to be addressed in the future to further increase knowledge of genetic testing and improve its use.
Read More